At week 52 , pazopanib , with allowance for as-needed ranibizumab injections , was noninferior to monthly ranibizumab as well as to as-needed ranibizumab administered with placebo eye drops in maintaining BCVA ( estimated BCVA gains of 0.3-1 .8 vs. 1.4 vs. 0.2 letters , respectively ) .